LeapFinancial | $3,500,000 | (Dec 20, 2024)
TG0 | $5,619,170 | (Dec 20, 2024)
Mindgard | $8,000,000 | (Dec 20, 2024)
FIGUR8, Inc.
United States
- Boston, MASSACHUSETTS
- 09/08/2023
- Series A
- $25,000,000
FIGUR8 has developed the first musculoskeletal diagnostics decision support system of its kind that can accurately pinpoint the source and severity of an injury while showing real-time recovery visibility to improve musculoskeletal health at every point of care — from injury through full recovery.
- Industry Hospital & Health Care
- Website https://figur8tech.com/
- LinkedIn https://www.linkedin.com/company/figur8/about/
Related People
Nan-Wei GongFounder
United States -
Cambridge, Massachusetts
Dr. Gong is currently the CEO of FIGUR8 Inc - the industry leader in transforming musculoskeletal (MSK) care with objective data and AI-driven biomarkers. Her work has been recognized by major news outlets such as the WSJ, Forbes, Bloomberg and INC.
In the past, she was on the award-winning founding team of 3dim Tech, gestural control for mobile devices (acquired in 2014); founder and managing partner of Circular2, an engineering consulting firm specializing in rapidly transforming ideas into production-ready products. Her clients include top universities, MIT and Harvard, as well as, Fortune 50 companies such as Google and Samsung. She was assigned as the R&D lead of Project Jacquard at Google ATAP from 2014-2017.
She received a Ph.D. from the MIT Media Lab in 2013. As an innovator driven by rigorous scientific and engineering training, she has published over 30 peer-reviewed papers, won two best paper awards at ACM CHI, and filed and granted over 10 US patents to date.
ŌURA | $200,000,000 | (Dec 20, 2024)
Buildpeer | $2,500,000 | (Dec 20, 2024)
Embeddable | $6,238,050 | (Dec 20, 2024)
Tenor | $5,400,000 | (Dec 20, 2024)
SOTELIX Endoscopy | $1,700,000 | (Dec 20, 2024)
Double(US) | $3,900,000 | (Dec 20, 2024)
Hauler Hero | $10,000,000 | (Dec 20, 2024)
TripSuite | $5,000,000 | (Dec 20, 2024)
Seekho | $8,000,000 | (Dec 19, 2024)